The Silverstein Foundation In the News
The Silverstein Foundation has been featured in national and international publications and broadcast media. Explore the thinks below to see and hear what others are saying about the Foundation and our Founder’s story.
Vanqua Bio closes $85 million Series B financing
Spurred on by OrbiMed partner’s diagnosis, Vanqua Bio takes aim at neurodegenerative disease with blue-chip backers
Silverstein Foundation Announces Grant Funding to AcureX Therapeutics.
The Silverstein Foundation for Parkinson’s with GBA today announced grant funding to AcureX Therapeutics to support the development of novel, first in class, small molecule drug candidates for the treatment of Parkinson’s disease (PD).
Prevail Therapeutics Acquired by Lilly
Acquisition will establish a gene therapy program at Lilly, anchored by Prevail’s portfolio of neuroscience assets, and will broaden Lilly’s commitment to use novel modalities to attempt to address otherwise fatal genetic forms of neurodegenerative disease.
Prevail Announces First Patient Dosed
Prevail Therapeutics Inc. (Nasdaq: PRVL), a biotechnology company developing potentially disease-modifying AAV-based gene therapies for patients with neurodegenerative diseases, today announced that the first patient has been dosed in the Phase 1/2 PROCLAIM clinical trial evaluating PR006, an investigational AAV9 gene therapy delivering the GRN gene, for the treatment of frontotemporal dementia patients with GRN mutations (FTD-GRN).
Prevail Therapeutics Granted Composition of Matter Patent for Experimental Gene Therapy Program PR001
Prevail Therapeutics Inc. today announced that the United States Patent and Trademark Office (USPTO) on November 17, 2020 issued a composition of matter patent, with claims directed to the AAV vector used in PR001, Prevail’s experimental gene therapy program for the treatment of Parkinson’s disease with GBA1 mutations (PD-GBA) and neuronopathic Gaucher disease (nGD).